Healius (ASX:HLS) is an Undervalued Healthcare Services Provider in a Growing Industry


Henry Fung

Henry is a co-founder of MF & Co. Asset Management with over 15 years of experience as a trader, investor and asset manager. Henry runs the Options Income Strategy and has a free 5-day options income strategy course you can take to learn how to use options to generate income.

October 8, 2020

Please note that any research that we publish does not take timing into consideration. We may publish research for a stock that we believe is of good quality but not necessarily trading at a discount or at a technical level for a high probability entry. If you would like to maximise your returns with optimised entry, exit and stop loss levels, check out our High Conviction Report.

Today we’ll look at why we like Healius shares (ASX:HLS) and we’ll give you a rundown of our HLS share price forecast.

Healius is a healthcare services provider with three main businesses – pathology, imaging and medical centres.

With an aging population and a growing pathology industry, Healius is well-positioned to take advantage of the growth in this industry.

Even though the company has underperformed recently, a lot of this can be attributed to COVID-19.

As the world starts to dig itself out of the COVID-19 issue, we should see a strong rebound in revenue as a backlog of revenue is realised.

With an NTM EV/EBITDA valuation 10x lower than the likes of Cochlear (ASX COH) and 3.4x lower than CSL (ASX CSL), Healius is a good option to get exposure to healthcare with more upside potential in lieu of the more expensive options.

About Healius Shares (ASX:HLS)

Healius (ASX HLS) is a healthcare company that provides support services and facilities to independent general practitioners, radiologists, and a range of other healthcare professionals.

The company engages in three main businesses – Pathology, Imaging and Medical Centres:


  • Pathology (72.5% of HLS’ revenue) is a medical specialty that focuses on determining the cause and nature of diseases.
  • Healius’ Pathology division is the second largest of Australia’s leading providers.


  • Advancements in diagnostic Imaging are opening new realms of possibilities for detecting and treating disease.
  • Imaging Services employs the latest technologies to provide affordable, accessible, and quality Imaging for all patients.

Medical Centre

  • Healius partners with over 1,500 independent general practitioners, dentists, specialists, and other healthcare practitioners who address both acute and chronic conditions in their patients.

Healius (ASX:HLS) - Market Share

Source: IBIS World

HLS share price historical performance

Healius (ASX HLS) - Historical Performance

Source: Morningstar

Over the last 2 years, the HLS share price outperformed the ASX by over 20%.

Strategic positioning

Healius is committed to positioning itself as a high-quality, consumer-centric healthcare services provider in the forefront of community healthcare sector delivering accessible services and creating value for its stakeholders.

Healius Shares (ASX:HLS) Business Strategy

Investment in R&D

Healius continuously invests in IT upgrades to core technology platforms, including investments in radiology through Imaging Core Application Refresh (iCAR) and a new Laboratory Information System (LIS) in Pathology.

Healius (ASX:HLS) - Historical IT Expense

Source: Morningstar, Healius annual report

Healius (ASX:HLS) - Capex OPRev & Bank gearing ratio

Source: Morningstar, Healius annual report

Business optimization

You may also like...
Iluka Resources (ASX:ILU): Rare Earths With Transformative Potential To Add To Heady Profits From Mineral Sands

The sale of the Healius Primary Care (HPC) has strengthened the balance sheet, achieved a more simplified business, and eliminated a capital-intensive unit (CAPEX/OPRev drops) within the group.

It allows Healius to focus more on Pathology, Imaging businesses and other emerging businesses that have foreseeable upsides.

Improved cost-saving

Healius is conducting a Sustainable Improvement Program (SIP) to reduce costs and improve efficiencies.

In FY2020, SIP has achieved $54 million savings and it aims to conduct SIP stage two to implement more complex but value-added structural improvements in FY2021.

Industry analysis

Pathology – a growing industry

Healius (ASX:HLS) - Revenue of Pathology and its drivers growth

Source: IBIS World

This industry is expected to grow in the next 5 years, driven by ageing populations and the number of births.

The increasing aging population (closed to 2% annual growth) and the prevalence of chronic conditions create a strong demand for pathology service.

Meanwhile, the annual births number reaches a new high (in 2016-17) despite the record-low fertility rate, creating demand for prenatal pathology services.

However, the revenue of pathology services is highly dependent on government funding and it is inherently subject to political uncertainty.

Healius (ASX:HLS) - Revenue of Pathology and its drivers growth

Source: IBIS World, Australian Bureau of Statistics

Key upsides for Healius Shares (ASX:HLS)

Flexibility in capital management & strengthened B/S

Healius shares will have a more flexible balance sheet and higher liquidity after the sale of HPC.

In June 2020, Healius announced a sale agreement with BGH Capital, which brings Healius $470 million cash proceed for sale of HPC.

Once the sale is completed, Healius will have free cash on hand to improve its core business (Pathology and Imaging), emerging business (IVF) or to conduct M&A.

Additionally, a significant reduction ($43 million) in capital expenditure resulted from discontinuing capital-intensive investment in HPC can also improve Healius shares’ profitability (FCF and ROIC).

Additionally, lower leverage in these uncertain times will act as a cushion to further insulate from impacts caused by COVID-19.

Specifically, Healius shares’ leverage of 2.7x Net Debt/EBITDA in FY2020 is below the covenant thresholds of bank gearing ratio (3.5x),

The HLS share price is undervalued in a growing industry

Healius (ASX:HLS) - EBITDA valuation vs. ASX 200 Healthcare

Source: FactSet

Healius (ASX:HLS) - EBITDA vs 3rd yr EBITDA

Source: FactSet, Goldman Sachs Global Investment Research

The HLS share price is undervalued among its peers.

In the healthcare sector, the ratio of HLS’ EV/EBITDA vs ASX 200 Healthcare as at a historical low.

Taking EBITDA growth into consideration, Healius shares is one of the cheapest firms (1.0x EV/EBITDA to growth ratio) in the sector.

Emerging business is improving profitability

Healius’ IVF business– “Adora Fertility” was loss-making because of its significant greenfield investment.

You may also like...
Stocks On The ASX To Watch This Week [11 April 2022]

Healius continue to optimise its service model through digitisation of delivery activities, social media campaigns and additional pricing mechanisms.

It delivered a 50% growth of revenue in July and positive profits in June and July after the easing of COVID-19 restrictions.

According to Goldman Sachs research, Adora Fertility is expected to deliver 10% EBIT margin in FY2021.

Sustainable Investment Program (SIP) delivers cost-saving

SIP initiated a target of $70 million annualised savings (4-5% of Group cost base).

In FY2020, over 150 initiatives were commenced and $37 million savings (53%) were achieved.

From FY2021, the program aims to deliver margin expansion, with a focus on addressing more complex but valuable structural improvements.

In particular, network optimisation by the closure of inefficient collection centres (10% of Healius’ current footprints) is expected to increase Healius’ profit margin by 50bps (Estimated by Goldman Sachs).

Key risks of Healius Shares (ASX:HLS)

COVID-19 impact

Revenue of Pathology recorded growth in FY20 due to average fee increase and revenue from COVID-19 testing which partially offset the COVID-19 impact in business-as-usual (BAU).

However, Imaging volumes rapidly declined since mid-March yet peaked in excess of 40% compared to the prior comparable period due to Victoria lockdowns.

With volatile testing volume, FY20 revenue was down 4% and EBIT recorded a decrease of 55%.

Overall, COVID-19 still poses risk to the volume of Pathology and Imaging and other business as well as income stream stability.

Healius (ASX:HLS) - Pathology volumes quarterly

Source: Medicare

Challenges from execution

Healius has not always reported the explicit track record in operational execution.

It may lead to higher uncertainty and lower accuracy in estimating future performance of SIP.

Moreover, Healius is likely to conduct M&A in a fragmented Australian Imaging industry and management will face inherent executive challenges.

Nevertheless, HLS is standing at the crossroads after the sale of HPC, and whether to focus on a simplified business portfolio or to develop its emerging businesses (Day hospitals & IVF) remains a big challenge to management.

Government funding

Healius providing affordable services by bulk-billing its services and receiving reimbursement from the Government.

Meanwhile, after the sale of HPC, Healius’ revenue becomes more concentrated.

Therefore, Group’s revenue and profitability will be more influenced by government funding schedule.

Healius Shares (ASX:HLS) Financial Performance

Healius (ASX:HLS) - Financial Performance

Source: Medicare

Healius (ASX:HLS) - Healius profitability measures

Source: Morningstar

The group’s underlying revenue in FY2020 recorded a 2% growth (eliminate HPC effect) but EBIT margin decreased to the lowest level over 6 financial years.

Specifically, strong trading performance in Pathology (EBIT growth of 4% to $115.1 million) and Montserrat Day Hospitals (EBIT growth of 520% to $3.1 million) during COVID-19 period partially offset the significant COVID-19-related decreases in Imaging (EBIT decrease of 55% to $17.2 million).

You may also like...
Coronado Global Resources (ASX:CRN) And Its Met Coal Are In A Sweet Spot Amidst Geo-Political And Economic Turmoil

Overall, Net profit for FY2020 was -$70.5 million, which also includes a $142.5 million loss from the sale of the HPC.

However, the Group’s financial performance is expected to normalise soon by a ‘backlog’ tailwind from the easing of COVID-19 restriction.

Healius Shares (ASX:HLS) Peer Comparison

Healius (ASX:HLS) - Peer Comparison

Source: Morningstar

Healius (ASX:HLS) - Pathology EBIT Margin and Imaging EBIT margins

Source: S&P Capital IQ, Goldman Sachs Investment Research

Healius (ASX:HLS) - Segment EBITDA

Source: S&P Capital IQ, Goldman Sachs Investment Research, MF & Co Asset Management Research

1The total EBITDA is calculated by excluding extraordinaries, negative and insignificant items

Constituent stocks in the ASX 200 Healthcare sector and Healius’ direct competitors (SHL & IDX) in Pathology and Imaging industry are selected to be the peers of Healius.

Healius shares underperformed in ROA and EBITDA margin, but it is expected to pick up.

Healius shares (ASX:HLS) have the lowest ROA (2.25%) and the 3rd lowest EBITDA (19.20%) margin compared to its peers.

Its profitability is currently far below the industry average.

However, as illustrated, pathology and imaging services dominate HLS’s income generation and the HLS is expected to contract the gaps between its pathology and imaging margins and its peers’.

Lowest P/B, P/E and EV/EBITDA ratio

The HLS share price is trading at the lowest valuation level among peers.

It has the lowest P/B and EV/EBITDA ratio, and the second-lowest P/E ratio.

Considering Healius reported a negative net profit, all the P/E ratio is calculated by using the pre-abnormal earnings (adjusted the non-recurring operations) per share.

Healius shares’ P/B ratio is at 0.98x compared to the median of 5.94x, P/E ratio at 23.11x in contrast to the median of 43.18x and EV/EBITDA at 11.57x against the industry median of 16.71x.

Overall, the HLS share price is one of the cheapest stocks in the Healthcare sector.


The HLS share price is undervalued with good growth potential.

In the short term, as COVID-19 restrictions ease, we expect an upward momentum in Pathology services and a sharp recovery in the Imaging and Day hospitals division, which may provide tailwinds for financial outperformance in FY21.

In the long run, we expect that Healius management would redirect its focus to the core business through the sale of HPC division and the cost-saving SIP program.

Healius’ low valuation resulted from recent underperformance presents a window of opportunity as we expect to see margin improvements in the long term.

Improvement in margins will see strong upside potential in the HLS share price.

Keep in mind that we publish research on stocks that are not necessarily trading at a discount or at a preferable technical level. If you want to maximise your returns by optimising your entry price, exit price and stop loss level, check out our High Conviction Report.

Are you still looking for the best stocks to buy in 2022? We’ve put together a free report on 5 stocks that we think are the best buys on the ASX right now. Download it instantly here.

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…


Want more Free Research?

Subscribe today for free and get an email with stocks to watch every Monday and new research every Thursday.

Invalid email address
We promise not to spam you. You can unsubscribe at any time.


What People are Saying...

See what people are saying about our research, products and services.

Timely advice, very informative and well researched.Very positive from a share trading view.
Brendon Beattie
Brendon Beattie
00:14 02 May 22
Nice reporting, thank you
Christophe Dussert
Christophe Dussert
07:16 23 Aug 21
Exceptional information that is concise and insightful. Keep up the great work !!!
09:19 19 Aug 21
I feel MF and Co are very informative with their advice and recommendations.
Norman Wilkins
Norman Wilkins
08:00 19 Aug 21
Good service with frequent emailed share suggestions.
Peter Farrell
Peter Farrell
03:39 19 Aug 21
Even I never trade with MF&Co, I watch all of Henry's review and analysis, very impressed with the accuracy and... objective of those thoughts.Of course no one can say what the future will be, but at least when reading those reviews, we know where we are, then sometimes that is the best thing that you can wish for.read more
Vu Nguyen
Vu Nguyen
23:44 15 Aug 21
Excellent service, not pushy, clear reporting highly recommended
Luke Stewart
Luke Stewart
23:25 15 Aug 21
Some very useful research
Richard Goodwin
Richard Goodwin
04:33 13 Aug 21
I very much appreciate the profound stock market research and the peceived honesty.
Quentin Steinbeck
Quentin Steinbeck
16:10 11 Aug 21
Easy to understand research for “dummies guide to shares trading”
Graham Ko
Graham Ko
15:30 09 Aug 21
Easily some of the most worthwhile research presented without any bias.
Tony Miller
Tony Miller
01:06 07 Aug 21
Nice free report with a good stock pick tip. Thank you.
00:17 06 Aug 21
i subscribed to the free research report and i found it very informative and useful for making investing decisions. I’m... looking forward to meet advisers in person when lockdown eases to learn futures options trading and to join trading education courses. Thanks for providing company reports for gratis 🙏read more
Rahul Newar
Rahul Newar
13:37 05 Aug 21
Excellent…..highly recommend
12:05 05 Aug 21
Henry's website is an absolute Treasure of Insightful Financial AdviceFree, Honest & Profitable!
Jonathan Meader
Jonathan Meader
11:37 05 Aug 21
I follow every recommendation and they are always a winner.
Peter Logiotatos
Peter Logiotatos
08:37 05 Aug 21
Great info, has helped in choosing some quality stocks to invest in and have had great results from those investments.
Stuart Farnworth
Stuart Farnworth
07:54 05 Aug 21
You can rarely find relevant, dedicated, and most importantly, free research as good as the ones published here.
07:26 05 Aug 21
Excellent and balanced with great knowledge
Peter Cryan
Peter Cryan
06:53 02 Aug 21
Great research and useful information for current market situation and potential buys.
May Deng
May Deng
06:04 02 Aug 21
great knowledge base and excellent research.
colin blanch
colin blanch
00:56 02 Aug 21
I am registered only on the free advice, I have found their advice to be so much more complete compared to other sites... which you have to pay for, it is timely and does not seem to be a shotgun approach as many sites seem to do so that some time in the future they can cherry pick their good results. For me 1 or 2 shares a week is so much more meaning to me for my style of investment, do I recommend MF& co, I sure do.read more
Phil O'Leary
Phil O'Leary
00:39 02 Aug 21
Ideas and complimentary assessments are informative, interesting and easy to read. They are sometimes 'out of box' in... thinking. To me, they install trust.read more
Grahame Cox
Grahame Cox
00:30 02 Aug 21
Informative information and well researched
David Bailey
David Bailey
00:12 02 Aug 21
Great research into current trends and foresight into what to watch for the future
00:03 02 Aug 21

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.


Get In Touch

1300 889 603
+61 2 8378 7199
M-F: 8am-5pm

Level 29, Chifley Tower
2 Chifley Square, NSW 2000


Share This